Annual EBITDA
-$14.05 M
-$2.42 M-20.80%
December 31, 2022
Summary
- As of February 18, 2025, NAVB annual EBITDA is -$14.05 million, with the most recent change of -$2.42 million (-20.80%) on December 31, 2022.
- During the last 3 years, NAVB annual EBITDA has fallen by -$3.23 million (-29.88%).
- NAVB annual EBITDA is now -789.34% below its all-time high of $2.04 million, reached on December 31, 2000.
Performance
NAVB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$2.10 M
+$296.30 K+12.34%
September 30, 2023
Summary
- As of February 18, 2025, NAVB quarterly EBITDA is -$2.10 million, with the most recent change of +$296.30 thousand (+12.34%) on September 30, 2023.
- Over the past year, NAVB quarterly EBITDA has stayed the same.
- NAVB quarterly EBITDA is now -400.01% below its all-time high of $701.40 thousand, reached on December 31, 2000.
Performance
NAVB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$8.89 M
+$2.82 M+24.09%
September 30, 2023
Summary
- As of February 18, 2025, NAVB TTM EBITDA is -$8.89 million, with the most recent change of +$2.82 million (+24.09%) on September 30, 2023.
- Over the past year, NAVB TTM EBITDA has stayed the same.
- NAVB TTM EBITDA is now -585.56% below its all-time high of $1.83 million, reached on March 31, 2001.
Performance
NAVB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NAVB EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.8% | 0.0% | 0.0% |
| 3 y3 years | -29.9% | 0.0% | 0.0% |
| 5 y5 years | -3.1% | 0.0% | 0.0% |
NAVB EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -20.8% | at low | -77.5% | +57.3% | at high | +36.7% |
| 5 y | 5-year | -32.0% | at low | -77.5% | +57.3% | at high | +36.7% |
| alltime | all time | -789.3% | +74.7% | -400.0% | +93.9% | -585.6% | +77.5% |
Navidea Biopharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$2.10 M(-12.3%) | -$8.89 M(-24.1%) |
| Jun 2023 | - | -$2.40 M(+102.5%) | -$11.71 M(-4.1%) |
| Mar 2023 | - | -$1.19 M(-62.9%) | -$12.21 M(-12.7%) |
| Dec 2022 | -$14.05 M(+20.8%) | -$3.20 M(-35.0%) | -$13.99 M(-0.5%) |
| Sep 2022 | - | -$4.93 M(+69.8%) | -$14.05 M(+21.9%) |
| Jun 2022 | - | -$2.90 M(-2.0%) | -$11.53 M(+2.2%) |
| Mar 2022 | - | -$2.96 M(-9.4%) | -$11.28 M(+0.1%) |
| Dec 2021 | -$11.63 M(+9.3%) | -$3.27 M(+35.9%) | -$11.27 M(+4.5%) |
| Sep 2021 | - | -$2.40 M(-9.3%) | -$10.78 M(-4.3%) |
| Jun 2021 | - | -$2.65 M(-10.1%) | -$11.26 M(+3.0%) |
| Mar 2021 | - | -$2.95 M(+5.9%) | -$10.93 M(+2.7%) |
| Dec 2020 | -$10.64 M(-1.6%) | -$2.78 M(-3.5%) | -$10.64 M(+0.4%) |
| Sep 2020 | - | -$2.88 M(+24.2%) | -$10.59 M(-1.6%) |
| Jun 2020 | - | -$2.32 M(-12.5%) | -$10.76 M(-2.8%) |
| Mar 2020 | - | -$2.65 M(-3.0%) | -$11.08 M(+2.4%) |
| Dec 2019 | -$10.82 M(+1.1%) | -$2.74 M(-10.3%) | -$10.82 M(+5.6%) |
| Sep 2019 | - | -$3.05 M(+15.7%) | -$10.25 M(-5.8%) |
| Jun 2019 | - | -$2.64 M(+10.0%) | -$10.88 M(+2.3%) |
| Mar 2019 | - | -$2.40 M(+10.7%) | -$10.63 M(-0.6%) |
| Dec 2018 | -$10.70 M(-21.5%) | -$2.16 M(-41.2%) | -$10.70 M(-10.9%) |
| Sep 2018 | - | -$3.68 M(+54.3%) | -$12.01 M(+12.6%) |
| Jun 2018 | - | -$2.39 M(-3.0%) | -$10.66 M(-18.1%) |
| Mar 2018 | - | -$2.46 M(-29.2%) | -$13.02 M(-4.4%) |
| Dec 2017 | -$13.62 M(+41.2%) | -$3.48 M(+48.9%) | -$13.62 M(+2.7%) |
| Sep 2017 | - | -$2.34 M(-50.8%) | -$13.26 M(+13.1%) |
| Jun 2017 | - | -$4.75 M(+55.1%) | -$11.73 M(+28.9%) |
| Mar 2017 | - | -$3.06 M(-1.8%) | -$9.10 M(-5.7%) |
| Dec 2016 | -$9.65 M(-46.0%) | -$3.12 M(+290.5%) | -$9.65 M(+8.6%) |
| Sep 2016 | - | -$798.30 K(-62.4%) | -$8.88 M(-27.6%) |
| Jun 2016 | - | -$2.12 M(-41.2%) | -$12.27 M(-11.1%) |
| Mar 2016 | - | -$3.61 M(+53.5%) | -$13.81 M(-22.7%) |
| Dec 2015 | -$17.87 M(-34.1%) | -$2.35 M(-43.9%) | -$17.87 M(-10.0%) |
| Sep 2015 | - | -$4.19 M(+14.5%) | -$19.85 M(-5.0%) |
| Jun 2015 | - | -$3.66 M(-52.2%) | -$20.90 M(-20.6%) |
| Mar 2015 | - | -$7.67 M(+76.8%) | -$26.33 M(-3.0%) |
| Dec 2014 | -$27.13 M(-28.7%) | -$4.34 M(-17.2%) | -$27.13 M(-20.2%) |
| Sep 2014 | - | -$5.24 M(-42.4%) | -$34.01 M(-12.8%) |
| Jun 2014 | - | -$9.09 M(+7.4%) | -$39.02 M(-1.5%) |
| Mar 2014 | - | -$8.47 M(-24.5%) | -$39.60 M(+4.1%) |
| Dec 2013 | -$38.03 M(+36.9%) | -$11.21 M(+9.4%) | -$38.03 M(+12.7%) |
| Sep 2013 | - | -$10.24 M(+5.9%) | -$33.76 M(+4.7%) |
| Jun 2013 | - | -$9.68 M(+40.2%) | -$32.25 M(+15.0%) |
| Mar 2013 | - | -$6.90 M(-0.5%) | -$28.03 M(+0.9%) |
| Dec 2012 | -$27.79 M(+11.8%) | -$6.94 M(-20.5%) | -$27.79 M(-6.9%) |
| Sep 2012 | - | -$8.73 M(+59.9%) | -$29.85 M(+8.4%) |
| Jun 2012 | - | -$5.46 M(-18.0%) | -$27.54 M(+7.5%) |
| Mar 2012 | - | -$6.66 M(-26.0%) | -$25.63 M(+3.1%) |
| Dec 2011 | -$24.86 M(-55.2%) | -$9.00 M(+40.2%) | -$24.86 M(+27.4%) |
| Sep 2011 | - | -$6.42 M(+81.1%) | -$19.51 M(+16.5%) |
| Jun 2011 | - | -$3.54 M(-39.8%) | -$16.74 M(+18.9%) |
| Mar 2011 | - | -$5.89 M(+61.4%) | -$14.08 M(+42.8%) |
| Dec 2010 | -$55.47 M(+3619.5%) | -$3.65 M(-0.1%) | -$9.86 M(+49.9%) |
| Sep 2010 | - | -$3.65 M(+316.0%) | -$6.58 M(+107.7%) |
| Jun 2010 | - | -$878.50 K(-47.5%) | -$3.17 M(+3.4%) |
| Mar 2010 | - | -$1.67 M(+351.6%) | -$3.06 M(+105.4%) |
| Dec 2009 | -$1.49 M(-29.0%) | -$370.70 K(+52.1%) | -$1.49 M(+20.6%) |
| Sep 2009 | - | -$243.80 K(-68.5%) | -$1.24 M(-50.7%) |
| Jun 2009 | - | -$774.20 K(+655.3%) | -$2.51 M(+43.3%) |
| Mar 2009 | - | -$102.50 K(-11.3%) | -$1.75 M(-6.3%) |
| Dec 2008 | -$2.10 M | -$115.60 K(-92.4%) | -$1.87 M(-94.8%) |
| Sep 2008 | - | -$1.52 M(+8925.0%) | -$36.05 M(+4.1%) |
| Jun 2008 | - | -$16.80 K(-92.4%) | -$34.62 M(-1.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$220.50 K(-99.4%) | -$34.99 M(-0.4%) |
| Dec 2007 | -$35.48 M(+1484.2%) | -$34.30 M(>+9900.0%) | -$35.15 M(+2321.6%) |
| Sep 2007 | - | -$90.00 K(-76.7%) | -$1.45 M(-39.2%) |
| Jun 2007 | - | -$385.90 K(+2.6%) | -$2.39 M(+5.2%) |
| Mar 2007 | - | -$376.10 K(-37.3%) | -$2.27 M(+1.4%) |
| Dec 2006 | -$2.24 M(-4.8%) | -$599.50 K(-41.6%) | -$2.24 M(-3.3%) |
| Sep 2006 | - | -$1.03 M(+281.9%) | -$2.32 M(+18.7%) |
| Jun 2006 | - | -$268.80 K(-22.1%) | -$1.95 M(-19.9%) |
| Mar 2006 | - | -$345.00 K(-49.0%) | -$2.44 M(+3.6%) |
| Dec 2005 | -$2.35 M(+105.9%) | -$677.00 K(+2.3%) | -$2.35 M(+3.6%) |
| Sep 2005 | - | -$661.70 K(-12.2%) | -$2.27 M(+39.4%) |
| Jun 2005 | - | -$753.60 K(+189.0%) | -$1.63 M(+48.4%) |
| Mar 2005 | - | -$260.80 K(-56.2%) | -$1.10 M(-3.9%) |
| Dec 2004 | -$1.14 M(+34.0%) | -$596.00 K(+2956.4%) | -$1.14 M(+23.8%) |
| Sep 2004 | - | -$19.50 K(-91.2%) | -$923.70 K(-27.6%) |
| Jun 2004 | - | -$222.20 K(-27.2%) | -$1.28 M(+41.4%) |
| Mar 2004 | - | -$305.40 K(-18.9%) | -$901.90 K(+5.7%) |
| Dec 2003 | -$853.30 K(-61.6%) | -$376.60 K(+1.5%) | -$853.30 K(+38.4%) |
| Sep 2003 | - | -$371.00 K(-345.5%) | -$616.40 K(-41.6%) |
| Jun 2003 | - | $151.10 K(-158.8%) | -$1.06 M(-43.9%) |
| Mar 2003 | - | -$256.80 K(+83.8%) | -$1.88 M(-15.4%) |
| Dec 2002 | -$2.22 M(-332.8%) | -$139.70 K(-82.8%) | -$2.22 M(+27.2%) |
| Sep 2002 | - | -$809.90 K(+19.8%) | -$1.75 M(+152.6%) |
| Jun 2002 | - | -$676.00 K(+12.9%) | -$692.50 K(-404.3%) |
| Mar 2002 | - | -$598.90 K(-278.5%) | $227.60 K(-76.2%) |
| Dec 2001 | $955.60 K(-53.1%) | $335.50 K(+35.9%) | $956.40 K(-27.7%) |
| Sep 2001 | - | $246.90 K(+1.1%) | $1.32 M(-12.4%) |
| Jun 2001 | - | $244.10 K(+87.9%) | $1.51 M(-17.5%) |
| Mar 2001 | - | $129.90 K(-81.5%) | $1.83 M(+11.2%) |
| Dec 2000 | $2.04 M(-150.6%) | $701.40 K(+61.5%) | $1.65 M(+74.3%) |
| Sep 2000 | - | $434.30 K(-23.2%) | $944.50 K(+85.1%) |
| Jun 2000 | - | $565.30 K(-1126.0%) | $510.20 K(-144.2%) |
| Mar 2000 | - | -$55.10 K(-95.0%) | -$1.16 M(-93.7%) |
| Dec 1999 | -$4.03 M(-85.2%) | - | - |
| Jun 1999 | - | -$1.10 M(-21.4%) | -$18.27 M(-16.1%) |
| Mar 1999 | - | -$1.40 M(-88.3%) | -$21.77 M(-21.3%) |
| Dec 1998 | -$27.20 M(+3.1%) | -$11.97 M(+215.0%) | -$27.67 M(+14.5%) |
| Sep 1998 | - | -$3.80 M(-17.4%) | -$24.16 M(-6.9%) |
| Jun 1998 | - | -$4.60 M(-37.0%) | -$25.96 M(-10.7%) |
| Mar 1998 | - | -$7.30 M(-13.8%) | -$29.06 M(+7.0%) |
| Dec 1997 | -$26.37 M(+16.2%) | -$8.46 M(+51.2%) | -$27.16 M(+3.7%) |
| Sep 1997 | - | -$5.60 M(-27.3%) | -$26.20 M(-4.0%) |
| Jun 1997 | - | -$7.70 M(+42.6%) | -$27.30 M(+10.1%) |
| Mar 1997 | - | -$5.40 M(-28.0%) | -$24.80 M(+6.4%) |
| Dec 1996 | -$22.70 M(+108.3%) | -$7.50 M(+11.9%) | -$23.30 M(+22.6%) |
| Sep 1996 | - | -$6.70 M(+28.8%) | -$19.00 M(+25.8%) |
| Jun 1996 | - | -$5.20 M(+33.3%) | -$15.10 M(+20.8%) |
| Mar 1996 | - | -$3.90 M(+21.9%) | -$12.50 M(+9.6%) |
| Dec 1995 | -$10.90 M(-2.7%) | -$3.20 M(+14.3%) | -$11.40 M(-5.0%) |
| Sep 1995 | - | -$2.80 M(+7.7%) | -$12.00 M(0.0%) |
| Jun 1995 | - | -$2.60 M(-7.1%) | -$12.00 M(+5.3%) |
| Mar 1995 | - | -$2.80 M(-26.3%) | -$11.40 M(+2.7%) |
| Dec 1994 | -$11.20 M(+38.3%) | -$3.80 M(+35.7%) | -$11.10 M(+13.3%) |
| Sep 1994 | - | -$2.80 M(+40.0%) | -$9.80 M(+6.5%) |
| Jun 1994 | - | -$2.00 M(-20.0%) | -$9.20 M(0.0%) |
| Mar 1994 | - | -$2.50 M(0.0%) | -$9.20 M(+15.0%) |
| Dec 1993 | -$8.10 M(+179.3%) | -$2.50 M(+13.6%) | -$8.00 M(+19.4%) |
| Sep 1993 | - | -$2.20 M(+10.0%) | -$6.70 M(+26.4%) |
| Jun 1993 | - | -$2.00 M(+53.8%) | -$5.30 M(+60.6%) |
| Mar 1993 | - | -$1.30 M(+8.3%) | -$3.30 M(+65.0%) |
| Dec 1992 | -$2.90 M | -$1.20 M(+50.0%) | -$2.00 M(+150.0%) |
| Sep 1992 | - | -$800.00 K | -$800.00 K |
FAQ
- What is Navidea Biopharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals annual EBITDA year-on-year change?
- What is Navidea Biopharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly EBITDA year-on-year change?
- What is Navidea Biopharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals TTM EBITDA year-on-year change?
What is Navidea Biopharmaceuticals annual EBITDA?
The current annual EBITDA of NAVB is -$14.05 M
What is the all time high annual EBITDA for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual EBITDA is $2.04 M
What is Navidea Biopharmaceuticals annual EBITDA year-on-year change?
Over the past year, NAVB annual EBITDA has changed by -$2.42 M (-20.80%)
What is Navidea Biopharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of NAVB is -$2.10 M
What is the all time high quarterly EBITDA for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly EBITDA is $701.40 K
What is Navidea Biopharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, NAVB quarterly EBITDA has changed by $0.00 (0.00%)
What is Navidea Biopharmaceuticals TTM EBITDA?
The current TTM EBITDA of NAVB is -$8.89 M
What is the all time high TTM EBITDA for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high TTM EBITDA is $1.83 M
What is Navidea Biopharmaceuticals TTM EBITDA year-on-year change?
Over the past year, NAVB TTM EBITDA has changed by $0.00 (0.00%)